Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | P4HB | P07237 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956520 | 1.00 | RAD51 (0.39) | RAD51ERN1P4HBCA1CA2 | |
| SCHEMBL29642158 | 0.96 | RAD51 (0.40) | RAD51ERN1P4HBCA1CA2 | |
| SCHEMBL29956507 | 0.84 | RAD51 (0.42) | RAD51ERN1P4HBCA1CA2 | |
| SCHEMBL124629 | 0.84 | RAD51 (0.42) | RAD51ERN1P4HBCA1CA2 | |
| SCHEMBL15777270 | 0.81 | CTSL (0.36) | RAD51ERN1P4HBCA1CA2 | |
| SCHEMBL1477364 | 0.81 | CYP11B1 (0.40) | ERN1 | |
| SCHEMBL23407049 | 0.80 | ERN1 (0.38) | ERN1CA1CA2 | |
| SCHEMBL2693856 | 0.80 | KIF11 (0.36) | RAD51P4HBCA2KIF11HSD17B14 | |
| SCHEMBL16956501 | 0.80 | P4HB (0.38) | RAD51P4HBCA2KIF11HSD17B14 | |
| SCHEMBL7195384 | 0.78 | RAD51 (0.40) | RAD51CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126771-A1 | PROCESS FOR PREPARING (Z)-3-(2-(5-BROMO-1H-INDOL-3-YL)-2-CYANOVINYL)-4-METHOXYBENZONITRILE | EVEXTA BIO (FR) | 2024-06-20 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-4720065-A1 | PRMT5 INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| CN-115720578-B | And tricyclic derivatives, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024245412-A1 | PRMT5 INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| CN-118359638-A | Compound serving as RET kinase inhibitor and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024124287-A1 | COMPOUNDS FOR TREATING VIRAL INFECTION | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024126771-A1 | PROCESS FOR PREPARING (Z)-3-(2-(5-BROMO-1H-INDOL-3-YL)-2-CYANOVINYL)-4-METHOXYBENZONITRILE | EVEXTA BIO (FR) | 2024-06-20 | — | — | WO | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000071512-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000026210-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999024395-A1 | COMPOUNDS WHICH INHIBIT TRYPTASE ACTIVITY | ARRAY BIOPHARMA, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | RAD51 3924/4885ERN1 1140/4885P4HB 4480/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | RAD51 1587/4885ERN1 2464/4885P4HB 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.